The client sought to transform its R&D bioinformatics capabilities, enabling efficient single-omic operations and facilitating multi-omics integration. They needed to harmonise data practices, define roles and responsibilities and plan a major organisational change.
We assessed existing capabilities, designed a technical and operational architecture and planned a transformation with support to harmonise multi-omics R&D.
Effective data-management strategies enable large organisations to leverage omics data for discovery. By harmonising processes and defining clear ownership, the client maximised its potential for innovation and efficiency.
Let’s discuss how we can turn your data into real scientific impact.
Contact us >
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.